Tri Locum Partners’s GSK GSK Stock Holding History

Tri Locum Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-409,503	Closed	-$12.1M	–	82
2022 Q3	$12.1M	Buy	+409,503	New	+$15.5M	3.31%	12

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Tri Locum Partners's GSK Position: Q4 2022 in Review

Tri Locum Partners sold out of GSK (GSK) in Q4 2022, closing a stake of 409,503 shares — an estimated $12.1M sold.

Tri Locum Partners first reported a position in GSK in Q3 2022 and held it in 1 quarter. The position peaked at $12.1M in Q3 2022. 813 funds tracked by Wall St. Rank hold GSK as of Q4 2022.

Tri Locum Partners reported no remaining GSK position as of Q4 2022 after selling out during the quarter.
Tri Locum Partners sold 409,503 GSK shares in Q4 2022, an estimated $12.1M.
Tri Locum Partners first reported a position in GSK in Q3 2022 and held it in 1 quarter.
Tri Locum Partners's GSK position peaked at $12.1M in Q3 2022.
813 funds tracked by Wall St. Rank held GSK as of Q4 2022.

Based on Tri Locum Partners's 13F filing for Q4 2022, filed 14 Feb 2023.